Drug intelligence / Profile preview

PL-18

Development stage: Phase 1
Lead developer: Jiangsu ProteLight Pharmaceutical & Biotechnology
Modality: Peptides, Small Molecules
Administration: Vaginal

Overview

PL-18 is a microbial cell membrane-modifying polypeptide, classified as an antimicrobial peptide. It is being developed in suppository form by Jiangsu Protelight Pharmaceutical for the treatment of bacterial infections, with a particular focus on gynecological applications. The drug acts by inhibiting quorum sensing (QS), virulence factors, iron uptake, and biofilm formation in bacteria. This multi-targeted mechanism suggests potential utility against antibiotic-resistant bacterial infections. As of recent clinical development, PL-18 has undergone phase I trials to evaluate its safety, tolerability, pharmacokinetics, and effects on vaginal flora in healthy adult female volunteers[1][2].

Other names: PL 18PL18PL-18

Beyond the preview

Go deeper on PL-18.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PL-18.

Explore the full profile